✦ LIBER ✦

Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration: PIER Study Year 1

✍ Scribed by Carl D. Regillo; David M. Brown; Prema Abraham; Huibin Yue; Tsontcho Ianchulev; Susan Schneider; Naveed Shams

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A prospective, randomized, double-masked

📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 253 KB

Bevacizumab vs ranibizumab for age-relat

✍ Subramanian, M L; Abedi, G; Ness, S; Ahmed, E; Fenberg, M; Daly, M K; Houranieh, 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 330 KB

Bevacizumab vs Ranibizumab for Age-Relat

✍ Manju L. Subramanian; Steven Ness; Gelareh Abedi; Ednan Ahmed; Mary Daly; Edward 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 740 KB

Bevacizumab vs Ranibizumab for Age-Relat

✍ Sean P. Donahue; Franco Recchia; Paul Sternberg Jr 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 80 KB

Ranibizumab for Treatment of Neovascular

✍ Jeffrey S. Heier; Andrew N. Antoszyk; Peter Reed Pavan; Steven R. Leff; Philip J 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 311 KB

Ranibizumab for Treatment of Neovascular

✍ Jeffrey S. Heier; Andrew N. Antoszyk; Peter Reed Pavan; Steven R. Leff; Philip J 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 311 KB